Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiac Science Gains Public AED Platform With Survivalink's FirstSave

This article was originally published in The Gray Sheet

Executive Summary

Cardiac Science Inc. will integrate its RHYTHMx ECD tachyarrhythmia detection and defibrillation software into Survivalink's FirstSave automatic external defibrillator (AED) product line following its acquisition of the Minneapolis-based firm, announced Feb. 14.

You may also be interested in...



Financings In Brief

Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...

Financings In Brief

Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...

Cardiac Science Powerheart Approval Revitalizes Stock In November

The possibility of the next-generation Powerheart bedside monitor-defibrillator emerging as a standard fixture in the acute-care setting helped to almost double Cardiac Science's stock price for November

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel